Business
LSL PHARMA GROUP SECURES $17.5 MILLION FROM DESJARDINS AND BDC
LSL PHARMA GROUP SECURES $17.5 MILLION FROM DESJARDINS AND BDC Canada NewsWire ...
About this update from Lsl Pharma Group Inc
[{"type":"text","content":"\n\n\n\n LSL PHARMA GROUP SECURES $17.5 MILLION FROM DESJARDINS AND BDC\n \n\n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n \n\n\n\n\n\n Canada NewsWire\n \n\n\n\n\n\n\n\n\n\n\n\n • Financing to include new\n \n $7.5 million\n \n line of credit from Desjardins and\n \n\n\n $10 million\n \n term loan from Desjardins and BDC\n \n\n\n\n\n BOUCHERVILLE, QC\n \n\n ,\n \n\n June 27, 2025\n \n\n /CNW/ -\n \n LSL PHARMA GROUP INC\n \n . (TSXV: LSL) (\"\n \n LSL Pharma\n \n \" or the \"\n \n Corporation\n \n \"), a Canadian integrated pharmaceutical company, today announced having secured a new\n \n $7.5 million\n \n operating line of credit (the \"New Line of Credit\") from Caisse Populaire Desjardins des Patriotes (\"Desjardins\") as well as new\n \n $10 million\n \n pari-passu term loan from BDC and Caisse Populaire Desjardins (the \"Term Loan\").\n \n\n The New Line of Credit which is now available, represents a\n \n $4.2 million\n \n increase over the prior combined line of credit from TD Bank and Scotia Bank. The Term Loan financing expected to close on or about\n \n July 7, 2025\n \n will be disbursed in three separate tranches. The first tranche to be disbursed on closing and serve to reimburse existing loans totalling\n \n $3.2 million\n \n plus accrued interest, as well as all outstanding Convertible Debentures listed as TSXV: LSL.DB, representing a principal amount of\n \n $3.288 million\n \n plus accrued interest (the \"Redemption\"). The Redemption will be subject to TSXV approval and a formal announcement and notice to Debenture holders, as per the terms of the Debenture Indenture dated\n \n November 1, 2023\n \n , which is available under LSL Pharma's issuer profile on\n \n www.sedarplus.ca\n \n .\n \n\n The second and third tranches will be used to fund capital expenditures and serve to reimburse other debts and loans. Disbursement of the second and third tranches is subject to certain conditions and is expected to be made available before the end of the current fiscal year. The New loan once fully disbursed, will help reduce the Corpo...